News

AddToAny

Google+ Facebook Twitter Twitter

Targeting the spread of pancreatic cancer

An international team of scientists has revealed how aggressive pancreatic cancer cells change their environment to enable metastasis – the main cause of pancreatic cancer-related death.

They discovered that some pancreatic tumours produce more of a molecule called “perlecan” to remodel the environment around them, which helps cancer cells spread around the body, and protects them against chemotherapy. 

In a mouse model, the researchers showed lowering the levels of perlecan revealed a reduction in the spread of pancreatic cancer and improved responses to chemotherapy.

The research may provide a promising new path to more effective treatment options for individuals with pancreatic and other cancers.

The work was led by Associate Professor Paul Timpson, Head of the Invasion and Metastasis Laboratory, and Dr Thomas Cox, Leader of the Matrix and Metastasis Group, at the Garvan Institute of Medical Research. 

Professor Timpson said: “Pancreatic cancer is very aggressive, and by the time most cases are diagnosed, the tumour is often inoperable. 

“What we’ve discovered in this study is a two-pronged approach for treating pancreatic cancer that we believe will improve the efficiency of chemotherapy and may help reduce tumour progression and spread.”

Image credit | iStock

Related Articles

My lab: diagnostic cytopathology and molecular

Specialist Biomedical Scientist Beth Carroll gives a guided tour of her laboratory in Cornwall.

Life in cytology (without cervical screening)

Consultant Biomedical Scientist Tracey Stevenson discusses developing a diagnostic cytology service after her previous laboratory was unsuccessful in bidding for cervical screening programme work.

Diffuse optics for diagnosticsDiffuse optics for diagnostics

Among the optics-based tools used in diagnostics, diffuse optics (DO) is rapidly emerging as one of the most attractive technologies.

Clinical andrology: overcoming barriers, improving outcomes

Clinical Scientist and Andrology Service Lead Stuart Long on the impact that taking on a patient-facing role can have.

Top